AngioDynamics (NASDAQ:ANGO) Stock Rating Upgraded by Freedom Capital

AngioDynamics (NASDAQ:ANGO) was upgraded by Freedom Capital to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, January 21st. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Finally, Canaccord Genuity Group dropped their price objective on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.67.

AngioDynamics Stock Up 5.6%

NASDAQ:ANGO traded up $0.55 during trading hours on Monday, reaching $10.25. The company had a trading volume of 107,440 shares, compared to its average volume of 568,846. The firm has a market cap of $422.42 million, a price-to-earnings ratio of -13.65 and a beta of 0.43. The business’s 50-day simple moving average is $10.83 and its two-hundred day simple moving average is $11.54. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $13.99.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $78.42 million during the quarter, compared to analysts’ expectations of $76.77 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. As a group, equities analysts predict that AngioDynamics will post -0.37 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ANGO. Goldman Sachs Group Inc. lifted its position in shares of AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after purchasing an additional 22,658 shares in the last quarter. Jane Street Group LLC lifted its position in shares of AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after purchasing an additional 34,054 shares in the last quarter. Legal & General Group Plc lifted its position in shares of AngioDynamics by 279.5% during the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 9,098 shares in the last quarter. Rhumbline Advisers lifted its position in shares of AngioDynamics by 4.3% during the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after purchasing an additional 2,510 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of AngioDynamics by 15.8% during the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after purchasing an additional 13,217 shares in the last quarter. 89.43% of the stock is owned by institutional investors.

Key Headlines Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Freedom Capital upgraded ANGO to “strong‑buy,” signaling increased confidence from a private/independent shop and likely attracting demand from momentum/upgrade‑driven investors. Freedom Capital Upgrade (Zacks)
• Positive Sentiment: HC Wainwright raised several near‑term and FY EPS estimates (Q1 & Q2 2027, FY2026 and FY2027, plus Q3/Q4 2027), narrowing expected losses and implying improving margins/operating performance — a clear fundamental catalyst supporting the stock. HC Wainwright Estimate Changes (MarketBeat)
• Positive Sentiment: AngioDynamics recently reported a quarterly beat with revenue up and losses narrowed (gross margin slipped), which validates the analyst upgrades and gives investors confidence about recovery in MedTech demand. Q3 Earnings Beat (Zacks)
• Neutral Sentiment: Canaccord Genuity cut its price target from $18 to $16 but kept a “buy” rating — this reduces the headline upside while still signaling conviction; the lower target may cap some near‑term gains despite the buy stance. Canaccord Price Target Change

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.